🇺🇸 FDA
Patent

US 10016399

Compositions and methods of treating cardiac fibrosis with ifetroban

granted A61KA61K31/421A61K31/422

Quick answer

US patent 10016399 (Compositions and methods of treating cardiac fibrosis with ifetroban) held by Cumberland Pharmaceuticals Inc. expires Mon Jul 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Cumberland Pharmaceuticals Inc.
Grant date
Tue Jul 10 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K31/421, A61K31/422, A61K9/00, A61K9/0019